Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Rakel MD, FAAFP
David Rakel MD, FAAFP Editor-in-Chief
Robert Bonakdar MD, FAAFP, FACN
Robert Bonakdar MD, FAAFP, FACN Advisory Board
Tricia Elliott MD, FAAFP
Tricia C. Elliott MD, FAAFP Associate Editor
See All Experts
featured
Published in Primary Care

Journal Scan / Research · June 20, 2019

Cardiovascular Safety of Oral Semaglutide in Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Peter Lin MD, CCFP

Diabetes, Obesity & Metabolism
Cardiovascular Safety of Oral Semaglutide in Patients With Type 2 Diabetes: Rationale, Design and Patient Baseline Characteristics for the PIONEER 6 Trial
Diabetes Obes Metab 2019 Mar 01;21(3)499-508, SC Bain, O Mosenzon, R Arechavaleta, P Bogdański, A Comlekci, A Consoli, C Deerochanawong, K Dungan, MC Faingold, ME Farkouh, DR Franco, J Gram, C Guja, P Joshi, R Malek, JF Merino-Torres, MA Nauck, SD Pedersen, WH Sheu, RJ Silver, CJ Tack, N Tandon, OK Jeppesen, M Strange, M Thomsen, M Husain

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated